247 related articles for article (PubMed ID: 34185901)
1. Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
Johnson TN; Ke AB
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S83-S93. PubMed ID: 34185901
[TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.
Wang K; Jiang K; Wei X; Li Y; Wang T; Song Y
AAPS PharmSciTech; 2021 Jul; 22(6):208. PubMed ID: 34312742
[TBL] [Abstract][Full Text] [Related]
4. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients.
Malik PRV; Edginton AN
CPT Pharmacometrics Syst Pharmacol; 2019 Nov; 8(11):835-844. PubMed ID: 31343836
[TBL] [Abstract][Full Text] [Related]
6. Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics.
Elmorsi Y; Barber J; Rostami-Hodjegan A
Drug Metab Dispos; 2016 Jul; 44(7):992-8. PubMed ID: 26712821
[TBL] [Abstract][Full Text] [Related]
7. Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.
Cheung KWK; van Groen BD; Burckart GJ; Zhang L; de Wildt SN; Huang SM
J Clin Pharmacol; 2019 Sep; 59 Suppl 1(Suppl 1):S56-S69. PubMed ID: 31502692
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetics (PBPK).
Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
[TBL] [Abstract][Full Text] [Related]
9. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Clearance in Neonates and Infants (≤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
Mahmood I; Ahmad T; Mansoor N; Sharib SM
J Clin Pharmacol; 2017 Apr; 57(4):476-483. PubMed ID: 27704554
[TBL] [Abstract][Full Text] [Related]
11. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents.
Mahmood I; Tegenge MA
J Clin Pharmacol; 2019 Feb; 59(2):189-197. PubMed ID: 30192373
[TBL] [Abstract][Full Text] [Related]
12. An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables.
van Rongen A; Krekels EH; Calvier EA; de Wildt SN; Vermeulen A; Knibbe CA
Expert Opin Drug Metab Toxicol; 2022 Feb; 18(2):99-113. PubMed ID: 35018879
[TBL] [Abstract][Full Text] [Related]
13. Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children.
Ince I; Dallmann A; Frechen S; Coboeken K; Niederalt C; Wendl T; Block M; Meyer M; Eissing T; Burghaus R; Lippert J; Willmann S; Schlender JF
J Clin Pharmacol; 2021 Jun; 61 Suppl 1(Suppl 1):S70-S82. PubMed ID: 34185905
[TBL] [Abstract][Full Text] [Related]
14. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups.
Liu XI; van den Anker JN; Burckart GJ; Dallmann A
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S94-S107. PubMed ID: 34185902
[TBL] [Abstract][Full Text] [Related]
16. Allometry Is a Reasonable Choice in Pediatric Drug Development.
Liu T; Ghafoori P; Gobburu JV
J Clin Pharmacol; 2017 Apr; 57(4):469-475. PubMed ID: 27649629
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic (PBPK) modeling in children.
Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
[TBL] [Abstract][Full Text] [Related]
18. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children.
Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38782791
[TBL] [Abstract][Full Text] [Related]
19. A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development.
Johnson TN; Small BG; Berglund EG; Rowland Yeo K
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):967-972. PubMed ID: 34288581
[TBL] [Abstract][Full Text] [Related]
20. State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.
Yellepeddi V; Rower J; Liu X; Kumar S; Rashid J; Sherwin CMT
Clin Pharmacokinet; 2019 Jan; 58(1):1-13. PubMed ID: 29777528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
